Cargando…

Humoral and cellular immunity to SARS-CoV-2 Ancestral and Omicron BA.5 variants following vaccination in myelofibrosis patients

Detalles Bibliográficos
Autores principales:	Alcheikh, Ahmad, Perkins, Griffith B., Pucar, Phillippa A., Cecchin, Amelia, Chai, Cheng Sheng, Tunbridge, Matthew, Akerman, Anouschka, Aggarwal, Anupriya, Milogiannakis, Vanessa, Turville, Stuart, Allen, Sharon, Hissaria, Pravin, Banovic, Tatjana, Coates, P. Toby, Ross, David M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083173/ https://www.ncbi.nlm.nih.gov/pubmed/37032391 http://dx.doi.org/10.1038/s41408-023-00824-8

Ejemplares similares

Rapamycin and inulin for booster vaccine response stimulation (RIVASTIM)—rapamycin: study protocol for a randomised, controlled trial of immunosuppression modification with rapamycin to improve SARS-CoV-2 vaccine response in kidney transplant recipients
por: Tunbridge, Matthew, et al.
Publicado: (2022)

SARS-CoV-2 Omicron BA.5: Evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern
por: Aggarwal, Anupriya, et al.
Publicado: (2022)

Enhanced stability of the SARS CoV-2 spike glycoprotein following modification of an alanine cavity in the protein core
por: Poumbourios, Pantelis, et al.
Publicado: (2023)

AstraZeneca ChAdOx1-S COVID-19 vaccine can be safely administered in patients with EDTA allergy
por: Ali, Syed B., et al.
Publicado: (2022)

COVID vaccination can be performed in patients with a history of allergic reactions to the vaccines or their components: experience from a specialist clinic in South Australia
por: Tunbridge, Matthew, et al.
Publicado: (2022)

Concurrent vaccination of kidney transplant recipients and close household cohabitants against COVID-19
por: Perkins, Griffith B., et al.
Publicado: (2022)

Multiple COVID-19 vaccine doses in CLL and MBL improve immune responses with progressive and high seroconversion
por: Shen, Yandong, et al.
Publicado: (2022)

Rapamycin and inulin for third-dose vaccine response stimulation (RIVASTIM): Inulin – study protocol for a pilot, multicentre, randomised, double-blinded, controlled trial of dietary inulin to improve SARS-CoV-2 vaccine response in kidney transplant recipients
por: Singer, Julian, et al.
Publicado: (2022)

Omicron Subvariants, Including BA.4 and BA.5, Substantially Preserve T Cell Epitopes of Ancestral SARS-CoV-2
por: Park, Kyemyung, et al.
Publicado: (2022)

SARS-CoV-2 Omicron BA.1 Challenge after Ancestral or Delta Infection in Mice
por: Baz, Mariana, et al.
Publicado: (2022)

High titre neutralizing antibodies in response to SARS–CoV–2 infection require RBD–specific CD4 T cells that include proliferative memory cells
por: Phetsouphanh, Chansavath, et al.
Publicado: (2022)

Durability of AZD1222 and hybrid humoral immunity against omicron BA.1 and BA.4
por: Soto-Rifo, Ricardo
Publicado: (2023)

Antibodies induced by ancestral SARS-CoV-2 strain that cross-neutralize variants from Alpha to Omicron BA.1
por: Windsor, Ian W., et al.
Publicado: (2022)

Neutralizing Antibodies against the SARS-CoV-2 Ancestral Strain and Omicron BA.1 Subvariant in Dogs and Cats in Mexico
por: Dehesa-Canseco, Freddy, et al.
Publicado: (2023)

Pfizer BNT 162b2 COVID-19 vaccine–induced fulminant myopericarditis: A case study
por: Montarello, Natalie L., et al.
Publicado: (2023)

Emergence and antibody evasion of BQ, BA.2.75 and SARS-CoV-2 recombinant sub-lineages in the face of maturing antibody breadth at the population level
por: Akerman, Anouschka, et al.
Publicado: (2023)

Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study
por: Ho-Yan Fong, Carol, et al.
Publicado: (2023)

Antigenic Cartography Indicates That the Omicron BA.1 and BA.4/BA.5 Variants Remain Antigenically Distant to Ancestral SARS-CoV-2 after Sputnik V Vaccination Followed by Homologous (Sputnik V) or Heterologous (Comirnaty) Revaccination
por: Astakhova, Ekaterina A., et al.
Publicado: (2023)

Myelofibrosis
por: Passamonti, Francesco, et al.
Publicado: (2023)

Third dose of BNT162b2 improves immune response in liver transplant recipients to ancestral strain but not Omicron BA.1 and XBB
por: Chang, Zi Wei, et al.
Publicado: (2023)

Humoral responses against SARS-CoV-2 Omicron BA.2.11, BA.2.12.1 and BA.2.13 from vaccine and BA.1 serum
por: Huo, Jiandong, et al.
Publicado: (2022)

Meloxicam-Induced Rhabdomyolysis in the Context of an Acute Ross River Viral Infection
por: Al Kindi, Mahmood, et al.
Publicado: (2012)

BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
por: Rössler, Annika, et al.
Publicado: (2022)

Myopericarditis following both BNT162b2 and NVX-CoV2373
por: Ahmad, Saima, et al.
Publicado: (2022)

Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013)

Dynamics of viral shedding during ancestral or Omicron BA.1 SARS-CoV-2 infection and enhancement of pre-existing immunity during breakthrough infections
por: Saade, Carla, et al.
Publicado: (2022)

Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections
por: Pedersen, Rune M., et al.
Publicado: (2022)

Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates
por: Routhu, Nanda Kishore, et al.
Publicado: (2023)

Long-term humoral response following Delta and Omicron BA.1 co-infection
por: Saade, Carla, et al.
Publicado: (2023)

SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine — Ohio and Rhode Island, September–November 2022
por: Canaday, David H., et al.
Publicado: (2023)

Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection
por: Khan, Khadija, et al.
Publicado: (2022)

Vaccine- and Breakthrough Infection-Elicited Pre-Omicron Immunity More Effectively Neutralizes Omicron BA.1, BA.2, BA.4 and BA.5 Than Pre-Omicron Infection Alone
por: Santos da Silva, Eveline, et al.
Publicado: (2023)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5
por: Muik, Alexander, et al.
Publicado: (2022)

BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection
por: Cao, Yunlong, et al.
Publicado: (2022)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Murine Models of Myelofibrosis
por: Jacquelin, Sebastien, et al.
Publicado: (2020)

Fibrocytes in primary myelofibrosis
por: Shimoda, Kazuya, et al.
Publicado: (2021)

The Role of Navitoclax in Myelofibrosis
por: Pandravada, Sasirekha, et al.
Publicado: (2021)

Osteolytic lesions in myelofibrosis
por: Johnson, Isla, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mcqhhpbnpgdutemmsu3bnmcpf2